EMA Withdrawn: Senstend (lidocaine;prilocaine) — Plethora Pharma Solutions Limited

View source ↗

Summary

EMA withdrew the Senstend (lidocaine; prilocaine) product from Plethora Pharma Solutions Limited, in the therapeutic area of premature ejaculation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• Senstend (lidocaine;prilocaine)

Snippet

Status: Withdrawn. Therapeutic area: Premature Ejaculation. MAH: Plethora Pharma Solutions Limited. Decision date: 14/11/2019